Retroperitoneal fibrosis following treatment for Hodgkin's disease.
With improvement and refinement of therapy, the majority of Hodgkin's disease patients are alive and free of disease at 5 years. As these patients continue to be observed, a variety of late complications have been reported. We describe herein three patients who developed retroperitoneal fibrosis following definitive therapy for Hodgkin's disease. The incidence approaches that seen with methysergide.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000009:adverse effects; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D011882:Radiotherapy, High-Energy / Q000009:adverse effects*; D012185:Retroperitoneal Fibrosis / Q000209:etiology*; D013997:Time Factors; D014517:Ureteral Obstruction / Q000209:etiology*; D014750:Vincristine / Q000009:adverse effects
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone